deniztural
@drdenizturalMedical Oncology, MD. Istanbul-Turkey
Similar User
@DrYukselUrun
@cdanicas
@Nejongy
@neerajaiims
@Derya83104817
@mumerrida
@dr_halilmutlu
@ilyas_tuncel55
@EnginYl29549535
@fdogan111
@weoncologists
@ErtugrulErik
@docthopex
@balim0201
@CFaillet
#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free…
📌 PATINA: a Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER-Positive Metastatic Breast…
The finding of no predictive biomarker underscores that there is more work to be done! Hats off to @DrChoueiri @motzermd @CPRT65 @JaimeMerchan10 et al for pushing for this biomarker work to be done.
CLEAR study biomarker analysis with @motzermd and friends is out in @Annals_Oncology —thank you EIC @tompowles1 for a flawless process! Lenvatinib + Pembrolizumab improved ORR/PFS vs. sunitinib in aRCC, consistent across PD-L1, gene expression, mutations, subtypes. No…
Hats off to Fernando Maluf for launching a groundbreaking RCT comparing XRT and RC in bladder cancer. This trial promises to answer a question that has eluded us for decades #BladderCancer @IBCG_BladderCA #GURetreat24
Amazing consensus meeting for relevant designs/endpoints for bladder preservation trials in MIBC! @AndreaNecchi @UroDocAsh @SpiessPhilippe @MattGalsky @shilpaonc @montypal @neerajaiims @emanuele_crupi @spsutkaMD @drjefstathiou @UroMoschini @GiorgioBre @Anto_cigliola @CMercinelli
NCCN guidelines now include ArteraAI's prostate cancer test! AI-driven analysis helps patients with low-risk prostate cancer & their doctors choose between active surveillance & definitive treatment. The test is becoming broadly available across the U.S. tinyurl.com/4whhfh4c
We are so excited for our long team effort published: PATRIOT-II study looking at RWD with avelumab switch maintenance after no PD after platinum chemo, link below: sciencedirect.com/science/articl… @sonpavde @PBarataMD @cnsternberg @shilpaonc @JasonBrownMDPhD @OncoAlert @OncBrothers
PATINA study of induction THP > maintenance HP + ET +/- palbo in ER+HER2+ MBC. Takeaway: after 6 cycles induction THP, patients can expect nearly 4 years of maintenance HP/ET/palbo on avg before re-needing chemo/ADC!
🆕📰New article in press: Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. @DrChoueiri
Triple Negatif Meme kanserinde ameliyat öncesi kemoterapi ve pembrolizumab kombinasyonu ile etkili sonuç elde etmek mümkün @drdeniztural profdrdeniztural.com/triple-negatif…
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. 🌟 Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing…
Does the extent of transurethral resection after radiation therapy impact survival outcomes in #MIBC? New study evaluates the impact of complete vs. incomplete TURBT after radiation therapy in. Results show no significant survival difference, but complete TURBT is linked to…
Evre IV Uveal Melanom tümörlerinde yeni tedavi seçeneği Tebentafusp-tebn @drdeniztural profdrdeniztural.com/evre-iv-uveal-…
Optimizing salvage radiation therapy in #ProstateCancer: New AUA/ASTRO/SUO Guideline. @wandering_gu @UMichUrology joins @zklaassen_md @GACancerCenter in this discussion of innovative approaches to prostate cancer management on UroToday > bit.ly/4dM3Nez
#RAPSON trial explores radium223 and docetaxel sequencing in #mCRPC. Vincenza Conteduca joins @neerajaiims to discuss trial design, preliminary results, and the importance of focusing on quality of life in mCRPC treatment. #WatchNow > bit.ly/4escKJD
ESMO 2024 Quick Take Insights: Prostate Cancer - #ARANOTE: Darolutamide + ADT shows significant rPFS benefits in mHSPC, offering a new treatment without docetaxel. - #PEACE-3: Radium-223 + enzalutamide in mCRPC enhances rPFS & OS when used with bone protection in patients with…
Emerging Neoadjuvant Combinations for Muscle-Invasive #BladderCancer. Mamta Parikh, MD, MS @ucdavis joins @UroCancerMD @VUMCurology to discuss the future of #MIBC therapy, highlighting innovative trials on chemo-IO combos, ADCs, and intravesical approaches for all cisplatin…
NURE-Combo trial: Neoadjuvant nivolumab + nab-paclitaxel achieved a 32.3% pathologic CR (ypT0N0) and 70.9% major pathologic response (ypT≤1N0-x) in MIBC. 12-month EFS: 89.8%. Promising results for cisplatin-ineligible patients! @AndreaNecchi @ASCO @JCO_ASCO #BladderCancer…
Clinical progression of #ProstateCancer from active surveillance is predicted by Decipher® genomic classifier score on index biopsy independent from risk assessment by MRI characteristic. Presented by Mark Sultan, MD @MayoClinic #SUO24 written coverage by @RKSayyid @USC >…
1/3 TROPICS-4: sacituzimab govitecan vs chemotherapy in heavily pretreated UC #ESMOasia24 @PGrivasMDPhD OS & PFS HR of 0.86, not significance. RR 23 vs 14, but G3+ TRAE 67 vs 35% with ⬆️ G5 TRD. While there is activity the ⬆️ tox & lower RR compared to EV/erda was problematic
United States Trends
- 1. Sam Howell 1.994 posts
- 2. Geno 12,8 B posts
- 3. Seahawks 26 B posts
- 4. Packers 37 B posts
- 5. Josh Allen 46,7 B posts
- 6. #GoPackGo 6.258 posts
- 7. #YellowstoneTV 5.881 posts
- 8. Lions 113 B posts
- 9. Bills 144 B posts
- 10. Josh Jacobs 7.458 posts
- 11. $EMT 4.394 posts
- 12. #BaddiesMidwest 6.502 posts
- 13. Dan Campbell 9.091 posts
- 14. Colts 34,5 B posts
- 15. Eagles 106 B posts
- 16. #RHOP 4.467 posts
- 17. Steelers 79,5 B posts
- 18. #VeryScaryPeople 2.549 posts
- 19. Klay 3.644 posts
- 20. Mona Lisa 21,5 B posts
Who to follow
-
Yüksel Ürün
@DrYukselUrun -
Daniel Castellano
@cdanicas -
Nejmettin Nogay
@Nejongy -
Neeraj Agarwal, MD, FASCO
@neerajaiims -
MRS.NURSE
@Derya83104817 -
Selma Sezer
@mumerrida -
HaLiL MuTLu
@dr_halilmutlu -
İlyas Tuncel
@ilyas_tuncel55 -
Engin Yıldız
@EnginYl29549535 -
faruk__dogan
@fdogan111 -
Gil Morgan, MD
@weoncologists -
ertuğrul
@ErtugrulErik -
Dr. Buket
@docthopex -
Halil İbrahim DAĞ
@balim0201 -
Caroline Faillet
@CFaillet
Something went wrong.
Something went wrong.